Home » Stocks » Acer Therapeutics

Acer Therapeutics Inc. (ACER)

Stock Price: $5.41 USD 0.94 (21.03%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $5.50 +0.09 (1.66%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 63.88M
Revenue (ttm) n/a
Net Income (ttm) -26.40M
Shares Out 11.81M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $5.41
Previous Close $4.47
Change ($) 0.94
Change (%) 21.03%
Day's Open 4.47
Day's Range 4.34 - 5.84
Day's Volume 3,033,837
52-Week Range 1.08 - 7.25

More Stats

Market Cap 63.88M
Enterprise Value 56.88M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 11.81M
Float 3.81M
EPS (basic) -2.61
EPS (diluted) -2.62
FCF / Share -2.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 378,795
Short Ratio 1.44
Short % of Float 6.17%
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.86
Revenue n/a
Operating Income -26.69M
Net Income -26.40M
Free Cash Flow -24.92M
Net Cash 7.01M
Net Cash / Share 0.59
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -55.09%
ROE -101.78%
ROIC 2,017.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 2
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$7.84*
(44.92% upside)
Low
3.52
Current: $5.41
High
10.00
Target: 7.84
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----2.561.271.27---
Revenue Growth----100.99%0.42%----
Gross Profit----2.561.271.27---
Operating Income-29.90-21.71-13.95-6.70-12.09-15.07-11.92-9.13-5.97-4.97
Net Income-29.42-21.28-14.19-6.70-12.02-15.05-16.66-8.93-5.97-5.47
Shares Outstanding10.098.563.692.450.570.340.160.070.070.05
Earnings Per Share-2.91-2.49-3.84-2.73-21.22-44.82-103.50-127.51-87.77-105.98
Operating Cash Flow-29.51-16.59-14.10-6.96-10.33-14.20-6.13-8.92-4.99-4.38
Capital Expenditures-0.18-0.10-0.06--0.09-0.19-0.26-0.55-0.30-0.04
Free Cash Flow-29.69-16.68-14.16-6.96-10.42-14.39-6.38-9.47-5.29-4.41
Cash & Equivalents12.0841.6715.641.8312.589.9123.641.597.113.81
Total Debt----0.150.15-0.38-0.04
Net Cash / Debt12.0841.6715.641.8312.449.7623.641.227.113.78
Assets21.4750.6624.372.7714.4211.8026.244.158.264.71
Liabilities3.105.582.030.824.804.365.661.261.070.75
Book Value18.3745.0822.34-10.189.627.4420.582.887.203.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acer Therapeutics Inc.
Country United States
Employees 18
CEO Christopher Schelling

Stock Information

Ticker Symbol ACER
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACER

Description

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.